India Glycols Limited Notifies NCLT Scheme Petition Hearing Scheduled for May 21, 2026
India Glycols Limited has submitted newspaper clippings to BSE and NSE under Regulation 30 of SEBI LODR Regulations, 2015, regarding the Notice of Hearing of its Scheme of Arrangement petition before the NCLT Allahabad Bench, Prayagraj. The petition under Sections 230 to 232 of the Companies Act, 2013, involves a demerger of India Glycols Limited into two resulting companies — Ennature Bio Pharma Limited and IGL Spirits Limited — with the hearing scheduled for May 21, 2026, following NCLT admission on April 9, 2026. The notice was advertised in Financial Express, Business Standard, and Uttar Ujala on May 5, 2026, with Mr. Hirak Mukhopadhyay of Khaitan & Co. acting as Counsel for the Petitioner Companies.

*this image is generated using AI for illustrative purposes only.
India Glycols Limited has filed a disclosure with the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, submitting newspaper clippings related to the Notice of Hearing of the Company Scheme Petition. The hearing before the Hon'ble National Company Law Tribunal (NCLT), Allahabad Bench, Prayagraj, is scheduled for May 21, 2026, as per the directions of the NCLT vide order dated April 9, 2026.
Scheme of Arrangement Details
The petition has been filed under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, read with the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016. The Scheme of Arrangement involves three petitioner companies and their respective shareholders, as detailed below:
| Parameter: | Details |
|---|---|
| Petitioner Company 1 / Demerged Company: | India Glycols Limited |
| Petitioner Company 2 / Resulting Company 1: | Ennature Bio Pharma Limited |
| Petitioner Company 3 / Resulting Company 2: | IGL Spirits Limited |
| Case Reference: | CP (CAA) No.07/ALD/2026 in CA (CAA) No.36/ALD/2025 (Second Motion) |
| NCLT Bench: | Allahabad Bench, Prayagraj |
| Order Admission Date: | April 9, 2026 |
| Hearing Date: | May 21, 2026 |
Newspaper Advertisement Publication
In compliance with Rule 16 of the Companies (Compromises, Arrangements and Amalgamation) Rules, 2016, the Notice of Hearing was advertised in the following newspapers on May 5, 2026:
- Financial Express (All Editions) — English
- Business Standard (All Editions) — English
- Uttar Ujala (Nainital Edition) — Hindi
Participation and Opposition Process
Any person desirous of supporting or opposing the petition is required to send a notice of intention, signed by themselves or their advocate along with their name and address, to the Advocates for the Petitioner Companies. Such notice must reach the Advocates not later than 7 (seven) days before the date fixed for the hearing, i.e., May 21, 2026. Persons seeking to oppose the petition are required to furnish the grounds of opposition or an affidavit along with the notice.
A copy of the Company Petition filed before the NCLT will be made available to any person requiring the same upon payment of prescribed charges. The Counsel for the Petitioner Companies is Mr. Hirak Mukhopadhyay of Khaitan & Co., Max Towers, 7th and 8th Floors, Sector 16B, Noida, Gautam Buddha Nagar 201 301, U.P.
Regulatory Compliance
The disclosure was made by Ankur Jain, Head (Legal) & Company Secretary of India Glycols Limited, vide letter reference IGL/SE/2026-27/06 dated May 5, 2026, addressed to the Manager (Listing) of BSE Limited and the National Stock Exchange of India Limited. The submission is in accordance with the requirements of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Historical Stock Returns for India Glycols
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.75% | +13.64% | +22.17% | +7.70% | +58.43% | +329.18% |
How will the demerger of Ennature Bio Pharma Limited and IGL Spirits Limited from India Glycols affect the parent company's revenue streams and long-term growth strategy?
What synergies or competitive advantages are Ennature Bio Pharma Limited and IGL Spirits Limited expected to unlock as independently listed entities post-demerger?
How might the NCLT approval or potential opposition at the May 21, 2026 hearing impact India Glycols' stock valuation and shareholder returns?


































